On one hand, frequent promoter methylation of COL1A1 has been observed in renal cell carcinoma and hepatocellular carcinoma, and COL1A2 downregulation has been reported in melanoma, head and neck cancer, and bladder cancer [27]. Here, COL1A2 is linked to urinary bladder cancer.